<code id='7436434F56'></code><style id='7436434F56'></style>
    • <acronym id='7436434F56'></acronym>
      <center id='7436434F56'><center id='7436434F56'><tfoot id='7436434F56'></tfoot></center><abbr id='7436434F56'><dir id='7436434F56'><tfoot id='7436434F56'></tfoot><noframes id='7436434F56'>

    • <optgroup id='7436434F56'><strike id='7436434F56'><sup id='7436434F56'></sup></strike><code id='7436434F56'></code></optgroup>
        1. <b id='7436434F56'><label id='7436434F56'><select id='7436434F56'><dt id='7436434F56'><span id='7436434F56'></span></dt></select></label></b><u id='7436434F56'></u>
          <i id='7436434F56'><strike id='7436434F56'><tt id='7436434F56'><pre id='7436434F56'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:entertainment    Page View:9
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In